Photoablation increases refractive index of stroma

Article

Photoablation increases the refractive index of the stroma following laser in situ keratomileusis (LASIK) surgery, according to a study published in the July 2008 issue of the Journal of Cataract and Refractive Surgery.

Photoablation increases the refractive index of the stroma following laser in situ keratomileusis (LASIK) surgery, according to a study published in the July 2008 issue of the Journal of Cataract and Refractive Surgery.

Sudi Patel, PhD of Practitioner Services, CSA, NHS Scotland, Edinburgh, UK and colleagues performed LASIK in 49 subjects (76 eyes) using either a microkeratome (M2; Moria) or a femtosecond laser (IntraLase; AMO). Patients undergoing surgery with a microkeratome (57 eyes) had a mean pre-surgical refractive index of 1.366±0.0049 SD; those treated with the femtosecond laser (19 eyes), 1.374±0.0047. After lifting the flap, the team measured the refractive index of the stroma before and immediately after photoablation.

Postoperatively, the mean refractive index of the microkeratome group was 1.382±0.0066; in the femtosecond group, it was 1.391±0.0102. Following ablation, both groups demonstrated a statistically significant increase in refractive index. A longer treatment time was associated with a greater increase in the refractive index.

Thus the researchers concluded that photoablation increases the refractive index of the stroma and that there exists a linear correlation between treatment time and the magnitude of refractive index improvement.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.